<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30655" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tuberculosis Screening</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>de Lima Corvino</surname>
            <given-names>Daniela F.</given-names>
          </name>
          <aff>Einstein Medical Center Philadelphia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shrestha</surname>
            <given-names>Sanjay</given-names>
          </name>
          <aff>Louisiana State University Health Shreveport/ Monroe</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hollingshead</surname>
            <given-names>Caitlyn M.</given-names>
          </name>
          <aff>The University of Toledo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kosmin</surname>
            <given-names>Aaron R.</given-names>
          </name>
          <aff>Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniela de Lima Corvino declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjay Shrestha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caitlyn Hollingshead declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aaron Kosmin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30655.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tuberculosis, caused by <italic toggle="yes">Mycobacterium tuberculosis, </italic>is an infection that occurs on a spectrum between latent and clinical disease. Clinical disease, termed active tuberculosis, is most frequently characterized by pulmonary disease, but extrapulmonary manifestations can also be observed.<xref ref-type="bibr" rid="article-30655.r1">[1]</xref> After initial infection, patients can progress to active tuberculosis or eliminate the organism via the innate immune response or T-cell immunity. Most are noted with latent tuberculosis infection (LTBI) characterized by <italic toggle="yes">M tuberculosis</italic> in a dormant state with no evidence of any symptoms.<xref ref-type="bibr" rid="article-30655.r2">[2]</xref><xref ref-type="bibr" rid="article-30655.r1">[1]</xref> These patients have the highest reactivation risk within the first two to five years of initial infection,&#x000a0;during which LTBI can progress to active tuberculosis.<xref ref-type="bibr" rid="article-30655.r1">[1]</xref> Lifetime reactivation risk is estimated at 5% to 10% and increases with immunosuppression.<xref ref-type="bibr" rid="article-30655.r3">[3]</xref> Therefore, those with LTBI are at risk for developing active tuberculosis and infecting others while risking personal morbidity and mortality. The global mortality of tuberculosis infection was estimated at 1.4 billion by the World Health Organization and 1.3 billion by the Global Burden of Disease study in 2013.<xref ref-type="bibr" rid="article-30655.r4">[4]</xref></p>
        <p>As patients with LTBI do not exhibit any symptoms, LTBI incidence has to be estimated. In 2014, the global incidence of latent tuberculosis infection (LTBI) calculated via mathematical modeling was 23%.<xref ref-type="bibr" rid="article-30655.r5">[5]</xref> An estimated 10.4 million new infections were noted in 2015.<xref ref-type="bibr" rid="article-30655.r6">[6]</xref> Screening for <italic toggle="yes">M tuberculosis</italic> infection is essential for public health, as it allows patients with LTBI to receive preventative treatment. The goal of testing for LTBI is the identification of those at high risk of developing tuberculosis. The decision to test should presuppose a decision to treat if the result is positive.<xref ref-type="bibr" rid="article-30655.r7">[7]</xref> Providers should be committed to following up on test results, offering tuberculosis-preventative treatment, and monitoring for adherence and tolerance of provided therapy.<xref ref-type="bibr" rid="article-30655.r7">[7]</xref></p>
        <p>The tuberculin skin test (TST) and the interferon-gamma release assay (IGRA) are the current screening methods for measuring adaptive host immune response.<xref ref-type="bibr" rid="article-30655.r8">[8]</xref> During initial infection, <italic toggle="yes">M tuberculosis </italic>is encountered by alveolar macrophages, and antigen is presented to T-cells.<xref ref-type="bibr" rid="article-30655.r9">[9]</xref> Upon second exposure, TH1 cells release IGN-&#x003b3;, which stimulates macrophages to release inflammatory cytokines.<xref ref-type="bibr" rid="article-30655.r9">[9]</xref> The TST measures the indirect evidence of this inflammatory reaction triggered by a reaction to purified protein derivative (PPD), a solution of antigens derived from <italic toggle="yes">M tuberculosis</italic>. In contrast, IGRAs measure the amount of IFN-&#x003b3; released.<xref ref-type="bibr" rid="article-30655.r9">[9]</xref></p>
      </sec>
      <sec id="article-30655.s2" sec-type="Specimen Collection">
        <title>Specimen Collection</title>
        <p>For interferon-gamma release assays, whole blood should be collected in evacuated, sterile tubes containing an anticoagulant and blood separation media.<xref ref-type="bibr" rid="article-30655.r10">[10]</xref> The "T-Spot" TB test requires the specimen to be processed on the collection day.<xref ref-type="bibr" rid="article-30655.r11">[11]</xref></p>
      </sec>
      <sec id="article-30655.s3" sec-type="Procedures">
        <title>Procedures</title>
        <p>
<bold>Tuberculin Skin Test (TST)</bold>
</p>
        <p>The TST measures the delayed hypersensitivity reaction to the purified protein derivative (PPD), a heat-inactivated tubercle bacilli protein precipitate.<xref ref-type="bibr" rid="article-30655.r9">[9]</xref><xref ref-type="bibr" rid="article-30655.r12">[12]</xref><xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>Five tuberculin units (0.1 mL) are injected intradermally on the volar surface of the forearm to form a 10 mm wheal (Mantoux method).<xref ref-type="bibr" rid="article-30655.r14">[14]</xref> This administration should be performed by skilled personnel. After placement, a follow-up visit in 48 to 72 hours is needed so the results can be interpreted.<xref ref-type="bibr" rid="article-30655.r14">[14]</xref> The greatest diameter of induration (not erythema) is measured in millimeters.<xref ref-type="bibr" rid="article-30655.r14">[14]</xref></p>
        <p>
<bold>Interferon Gamma Release Assays (IGRAs)</bold>
</p>
        <p>Two assays are approved by the United States Food and Drug Administration and the WHO: the QuantiFERON-TB Gold Plus (QFT-Plus)&#x000a0;test&#x000a0;and the T-SPOT.TB (T-Spot)&#x000a0;test.<xref ref-type="bibr" rid="article-30655.r15">[15]</xref> The QuantiFERON-TB Gold Plus replaced its predecessor, the QuantiFERON-TB Gold In-Tube, which is no longer commercially available.<xref ref-type="bibr" rid="article-30655.r15">[15]</xref></p>
        <p>The QFT-Plus test is an enzyme-linked immunosorbent assay measuring IFN-&#x003b3; release in&#x000a0;4 tubes: a negative control (nil), a positive control (mitogen), a tube containing ESAT-6 and CFP-10 antigens (TB1 antigen) that measures mainly CD4 T-cell response, and a tube containing shorter ESAT-6 and CFP-10 antigens (TB2 antigen) that measures both CD4 and CD8 T-cell response.<xref ref-type="bibr" rid="article-30655.r15">[15]</xref> Due to sharing ESAT-6 with <italic toggle="yes">M tuberculosis</italic>, there is cross-reactivity in patients infected with certain non-tuberculous mycobacteria, including&#x000a0;<italic toggle="yes">M kansasii</italic>, <italic toggle="yes">M marinum</italic>, <italic toggle="yes">M szulgai</italic>, and <italic toggle="yes">M riyadhense</italic>.<xref ref-type="bibr" rid="article-30655.r16">[16]</xref> Results are either positive, negative, or indeterminate.<xref ref-type="bibr" rid="article-30655.r17">[17]</xref></p>
        <p>The T-Spot test is an enzyme-linked immunospot assay in which the patient's mononuclear cells are incubated in microwells on assay plates containing positive control, negative control, ESAT-6, or CFP-10 peptides.<xref ref-type="bibr" rid="article-30655.r18">[18]</xref> Positive microwells, representing T-cells capable of releasing cytokine, are counted after incubation.<xref ref-type="bibr" rid="article-30655.r18">[18]</xref> Positive ESAT-6 and CFP-10 microwells are subtracted from positive or negative control wells. Results are either positive, negative, borderline, or invalid.<xref ref-type="bibr" rid="article-30655.r19">[19]</xref></p>
        <p>Since the immune reaction is performed ex vivo in the laboratory, only one visit is needed for a single blood draw, and the results are available in 24 to 48 hours. Also, cross-reaction with antigens of <italic toggle="yes">M bovis&#x000a0;</italic>bacillus Calmette-Gu&#x000e9;rin (BCG) vaccination is not a consideration with these tests.<xref ref-type="bibr" rid="article-30655.r20">[20]</xref><xref ref-type="bibr" rid="article-30655.r15">[15]</xref> IGRA methods are preferred for individuals who may not return for a TST reading and patients&#x000a0;younger than&#x000a0;5.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>In addition to the QFT-Plus and the T-Spot approved by the US Food and Drug Administration,&#x000a0;5 newer IGRAs are available: T-Spot.TB/T-Cell select, QFT-Plus CLIA, Standard E TB-Feron, QIAreach, and the TB-IGRA.<xref ref-type="bibr" rid="article-30655.r21">[21]</xref> The TB-IGRA was found to have very similar sensitivity and specificity to approved IGRAs.<xref ref-type="bibr" rid="article-30655.r21">[21]</xref> It has additionally been approved for use by the WHO.</p>
      </sec>
      <sec id="article-30655.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Screening should be performed on those at high risk for infection. Those at high risk include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Recent exposure to persons with active tuberculosis, including all household contacts.<xref ref-type="bibr" rid="article-30655.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Residents and employees of congregate facilities with high risk (eg, homeless shelters, correctional facilities, refugee centers, nursing homes).<xref ref-type="bibr" rid="article-30655.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Immigrants from tuberculosis-endemic regions (more than&#x000a0;20 cases per 100,000 persons).<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Persons working with <italic toggle="yes">M tuberculosis</italic> in mycobacterial laboratories.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Healthcare workers that work with a high-risk population.<xref ref-type="bibr" rid="article-30655.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>Additionally, screening should be performed on individuals with conditions or other factors associated with progression to active disease (reactivation):</p>
        <list list-type="bullet">
          <list-item>
            <p>High risk: certain immunocompromising conditions, such as patients with HIV/AIDS, preparing for or have undergone organ transplantation, preparing to receive or receiving tumor necrosis factor (TNF) inhibitor therapy or other biologics, with end-stage renal failure on dialysis, malignancy, or silicosis.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref><xref ref-type="bibr" rid="article-30655.r23">[23]</xref> Additionally, those with recent tuberculosis infection in the past&#x000a0;2 years with radiographic evidence of prior healed tuberculosis or a history of untreated or inadequately treated tuberculosis are considered at high risk.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref><xref ref-type="bibr" rid="article-30655.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Moderate risk: chronic steroid use (greater than 15 milligrams per day of prednisone equivalent), diabetes mellitus, and those at a young age (&#x0003c;5 years) when infected.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref><xref ref-type="bibr" rid="article-30655.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p>Increased risk: cigarette smoking, drug use, alcohol use disorder, body mass index of less than 20, or solitary granuloma on chest radiograph.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref><xref ref-type="bibr" rid="article-30655.r23">[23]</xref></p>
          </list-item>
        </list>
        <p>Screening should be done with the intent to treat if the result is positive.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> Chest radiography should be obtained.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> If there are findings that could be consistent with active pulmonary tuberculosis, such as cavitation, airspace opacities, pleural effusions, or fibrotic changes, active pulmonary tuberculosis should be ruled out with&#x000a0;3 serial acid-fast bacilli (AFB) sputum cultures collected&#x000a0;8 hours apart with one being an early morning sample.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> If all&#x000a0;3 AFB sputum smears are negative, active tuberculosis has been ruled out, and testing and offering tuberculosis-preventative therapy for LTBI can be considered.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> Ziehl-Neelsen stain is often utilized for this smear, which employs carbolfuchsin and methylene blue dyes.<xref ref-type="bibr" rid="article-30655.r24">[24]</xref></p>
        <p>It is not recommended that patients with low risk for LTBI and no risk factors for disease progression be tested.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> However, if required by the law or a credentialing body, an IGRA is recommended in those over&#x000a0;5 years old, and if positive, a confirmatory TST is recommended.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> Patients should only be prescribed TB-preventative treatment if both tests are positive.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>
<bold>Test Selection</bold>
</p>
        <p>Centers for Disease Control, The Infectious Diseases Society of America, and World Health Organization guidelines endorse using IGRA or TST to screen for tuberculosis.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref><xref ref-type="bibr" rid="article-30655.r23">[23]</xref> In certain situations, one test is preferred over the other.</p>
        <p>The TST is the test of choice for children younger than&#x000a0;5 or when there is a concern for a waning immune response, as the TST has a boosting effect.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> The TST may be somewhat preferred for patients, such as healthcare workers, who need repeat testing annually because IGRA test results may be less reproducible.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> Issues with the reproducibility of IGRAs stem from several factors, including specimen handling, manufacturing processes, and immunological considerations, such as prior boosting with a TST.<xref ref-type="bibr" rid="article-30655.r25">[25]</xref></p>
        <p>IGRAs are recommended for patients who may not return for the TST reading (people who use drugs, those with housing insecurity),&#x000a0;those who have previously received BCG vaccination, or individuals older than&#x000a0;5&#x000a0;who are likely to be infected with <italic toggle="yes">M tuberculosis </italic>and have a low or intermediate risk of disease progression.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> The area of induration of the TST has been shown to increase proportionally to the number of BCG vaccinations.<xref ref-type="bibr" rid="article-30655.r26">[26]</xref> However, using traditional cutoffs, the TST remains a valuable tool in diagnosing LTBI.<xref ref-type="bibr" rid="article-30655.r27">[27]</xref></p>
        <p>It is unclear which test modality is preferable in individuals&#x000a0;5 years or older with a high risk of progression to disease. TST should be done when IGRA is unavailable, too costly, or difficult to perform.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>Simultaneous or sequential testing is not recommended, except in cases where the initial test is negative, indeterminate, or borderline if the clinical suspicion is high. In that case, repeat testing with TST or IGRA (depending on which test was done initially) can be done. Additionally, the TST or IGRA should not be repeated if they were previously positive or to follow therapy, as this positive result is expected to be retained, and differences in results are challenging to interpret.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>TST and IGRAs are used to diagnose LTBI and should not be used to exclude the possibility of active tuberculosis.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> Both tests can be falsely negative in the setting of active disease.<xref ref-type="bibr" rid="article-30655.r28">[28]</xref> Other testing modalities, such as chest imaging and sputum collection, should be employed if active tuberculosis is suspected.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
      </sec>
      <sec id="article-30655.s5" sec-type="Normal and Critical Findings">
        <title>Normal and Critical Findings</title>
        <p>
<bold>Interpreting the TST</bold>
</p>
        <p>Interpretation criteria for a positive result of the TST can be found in the following table.<xref ref-type="bibr" rid="article-30655.r29">[29]</xref></p>
        <table-wrap id="article-30655.table0" position="float" orientation="portrait">
          <table style="width: 800px; border-color: black;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>&#x02265;5 mm Induration</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>&#x02265;10 mm Induration</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>&#x02265;15 mm Induration</bold>
</td>
              </tr>
              <tr style="height: 98.8px;">
                <td style="height: 98.8px;" rowspan="1" colspan="1">HIV infection</td>
                <td style="height: 98.8px;" rowspan="1" colspan="1">
<p>Certain medical conditions:</p>
<p>End-stage renal disease on hemodialysis</p>
<p>Silicosis</p>
<p>Diabetes mellitus</p>
<p>Hematological malignancy or head and neck carcinoma</p>
<p>History of jejunoileal bypass or gastrectomy</p>
</td>
                <td style="height: 98.8px;" rowspan="1" colspan="1">No risk factors for tuberculosis</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Recent contact with a person with active tuberculosis</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Loss of &#x0203a;10% of ideal body weight</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Abnormal chest radiography with fibrotic changes</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Active injection drug use</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 111px;">
                <td style="height: 111px;" rowspan="1" colspan="1">
<p>Immunosuppression due to:</p>
<list list-type="bullet"><list-item><p>Organ transplantation</p></list-item><list-item><p>&#x0203a; 15 mg/day prednisone or equivalent corticosteroid dosing for one month or more</p></list-item><list-item><p>TNF antagonist use</p></list-item><list-item><p>Other biologic use</p></list-item></list>
</td>
                <td style="height: 111px;" rowspan="1" colspan="1">Age younger than 4, or children at any age with exposure to adults at high risk</td>
                <td style="height: 111px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="height: 13px;" rowspan="1" colspan="1">Personnel of a mycobacterial laboratory or other occupational exposure</td>
                <td style="height: 13px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 26px;">
                <td style="height: 26px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="height: 26px;" rowspan="1" colspan="1">People from countries with a high incidence of tuberculosis who immigrated within the last five years</td>
                <td style="height: 26px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 98px;">
                <td style="height: 98px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="height: 98px;" rowspan="1" colspan="1">
<p>Residents and employees of:</p>
<list list-type="bullet"><list-item><p>Prisons</p></list-item><list-item><p>Jails</p></list-item><list-item><p>Healthcare facilities</p></list-item><list-item><p>Homeless or refugee shelters</p></list-item></list>
</td>
                <td style="height: 98px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>&#x000a0;If a TST is positive in a situation of high to above baseline risk:</p>
        <list list-type="bullet">
          <list-item>
            <p>The test should not be repeated.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>A chest radiograph and clinical evaluation for the potential of active tuberculosis should be obtained.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>If no evidence of active disease is noted by history, physical examination, or radiography, the patient should be deemed to have LTBI and given tuberculosis-preventative treatment.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>If the chest radiograph or clinical evaluation suggests active tuberculosis, then active infection must be excluded with further testing.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>Evaluating the potential of active tuberculosis is imperative, as therapy for LTBI consists of&#x000a0;1 to&#x000a0;2 active agents, which is insufficient for treating active tuberculosis and can promote resistance.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>If the TST is negative, experts' opinion outlines that repeat testing with another TST or an IGRA is reasonable if the patient is at high risk of infection progression or recent infection for further evaluation for the possibility of a false negative test.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> However, not all of these cases would be amenable to repeat testing, and decisions to retest should be made on a case-by-case basis. Attention should be drawn to situations in which repeat testing may be considered due to the increased risk of a false negative test:</p>
        <list list-type="bullet">
          <list-item>
            <p>TST can be negative in cases where testing occurs within the first&#x000a0;8 weeks of exposure when the immune response has not developed yet or in patients with remote tuberculosis exposure where the tuberculin reaction might have waned.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref><xref ref-type="bibr" rid="article-30655.r30">[30]</xref><xref ref-type="bibr" rid="article-30655.r31">[31]</xref> At times, these&#x000a0;2 situations may be difficult to distinguish.</p>
            <list list-type="bullet">
              <list-item>
                <p>In the former group, a second TST test placed after the first&#x000a0;8 weeks post-exposure will often be positive.<xref ref-type="bibr" rid="article-30655.r31">[31]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>In the latter group, consisting primarily of older adults, a second TST ("booster") applied a couple of weeks later often will be positive.<xref ref-type="bibr" rid="article-30655.r31">[31]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>A repeat positive second test increases the sensitivity for detecting LTBI in immunocompromised patients.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> However, a negative test in this context can result from a lack of ability to mount an immune response rather than the absence of LTBI.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> The likelihood of the diagnosis, considering potential exposure history, has to be used in this setting to decide whether or not to provide TB-preventative treatment, with a thorough consideration of the risks of offering and withholding TB-preventative therapy. A case-by-case evaluation is critical.</p>
          </list-item>
        </list>
        <p>Alternatively, a false positive test should be suspected in low-risk patients for prior exposure or disease progression.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> For this reason, these patients should not be tested unless otherwise mandated.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>In patients vaccinated with BCG and have a positive PPD reaction, the positive result is more likely due to tuberculosis exposure than the remote vaccination, and the immunization history should be disregarded when considering whether to offer TB-preventative therapy.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> IGRA tests are advantageous in this situation, as these are unaffected by prior BCG vaccination.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <p>For healthcare workers and occupational exposure risk, the Centers for Disease Prevention recommend that United States healthcare workers receive LTBI screening, which should be repeated yearly and at hire.<xref ref-type="bibr" rid="article-30655.r32">[32]</xref> As those with LTBI infection are most likely to progress to active infection within the first&#x000a0;2 years of disease, such screening optimizes the impact of LTBI treatment.<xref ref-type="bibr" rid="article-30655.r1">[1]</xref></p>
        <p>
<bold>Interpreting IGRA</bold>
</p>
        <p>Results are reported as indeterminate, positive, or negative. An indeterminate test signifies a weak response of TH1 cells to the positive control (low mitogen) or a strong response to the negative control (high nil).<xref ref-type="bibr" rid="article-30655.r33">[33]</xref> Both values are reported so that it is known to which situation an indeterminate test can be attributed.<xref ref-type="bibr" rid="article-30655.r34">[34]</xref>&#x000a0;Indeterminate tests due to a strong response to the negative control occur in cases of high background immune activity with high initial levels of IFN-&#x003b3;, such as in rheumatologic states, or weak response to the positive control, such as immunosuppression.<xref ref-type="bibr" rid="article-30655.r35">[35]</xref> Indeterminate results are due to low mitogen response an overwhelming majority of the time.<xref ref-type="bibr" rid="article-30655.r35">[35]</xref><xref ref-type="bibr" rid="article-30655.r17">[17]</xref></p>
        <p>A meta-analysis involving 486,886 patients screened for LTBI noted that 3.9% had an indeterminate IGRA.<xref ref-type="bibr" rid="article-30655.r17">[17]</xref> Immunosuppressed patients had a higher rate of indeterminate tests, and the rate of indeterminate tests increased as the CD4 count decreased in HIV-positive patients.<xref ref-type="bibr" rid="article-30655.r17">[17]</xref> Additionally, higher rates were noted in children, and rates decreased as the age of children increased.<xref ref-type="bibr" rid="article-30655.r17">[17]</xref> One study involving immigrants to the United States found that Asian race and the combination of anemia and hypoalbuminemia were independent risk factors for an indeterminate test.<xref ref-type="bibr" rid="article-30655.r35">[35]</xref></p>
      </sec>
      <sec id="article-30655.s6" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>The varying causes of the TST's false positive and false negative results are outlined in the table below.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
        <table-wrap id="article-30655.table1" position="float" orientation="portrait">
          <table style="border-color: black; width: 800px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">
<bold>False Positive</bold>
</td>
                <td style="text-align: center;" rowspan="1" colspan="1">
<bold>False Negative</bold>
</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">Prior BCG vaccination</td>
                <td style="text-align: center;" rowspan="1" colspan="1">Anergy due to immunosuppression</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">
<p>Exposure to environmental mycobacteria</p>
</td>
                <td style="text-align: center;" rowspan="1" colspan="1">
<p>The natural waning of immunity</p>
</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">Incorrect application</td>
                <td style="text-align: center;" rowspan="1" colspan="1">Recent tuberculosis infection (within 8 to 10 weeks)</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">Incorrect interpretation</td>
                <td style="text-align: center;" rowspan="1" colspan="1">Recent viral infection or concurrent bacterial infection</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="text-align: center;" rowspan="1" colspan="1">Advanced tuberculosis</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="text-align: center;" rowspan="1" colspan="1">Extremes of age</td>
              </tr>
              <tr>
                <td style="text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="text-align: center;" rowspan="1" colspan="1">Improper technique or interpretation of test</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Interreader variability should be highlighted as a significant cause of false-positive and false-negative results. Results have been shown to vary up to 15% between different personnel interpreting the test.<xref ref-type="bibr" rid="article-30655.r8">[8]</xref> This figure increases when those with little prior experience read the test.<xref ref-type="bibr" rid="article-30655.r8">[8]</xref></p>
        <p>In contrast, IGRAs are not affected by prior BCG immunization.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref> However, due to sharing ESAT-6 with <italic toggle="yes">M tuberculosis</italic>, there is cross-reactivity between previous exposure to <italic toggle="yes">M marinum</italic>, <italic toggle="yes">M kansasii</italic>, <italic toggle="yes">M szulgai</italic>, and <italic toggle="yes">M riyadhense.</italic><xref ref-type="bibr" rid="article-30655.r16">[16]</xref></p>
        <p>A meta-analysis of studies measuring the performance of the QFT-Plus performed in 2021 found that it had a sensitivity of 91.4% and a specificity of 97.8%.<xref ref-type="bibr" rid="article-30655.r36">[36]</xref> The sensitivity of the TST is between 95% and 98%.<xref ref-type="bibr" rid="article-30655.r13">[13]</xref></p>
      </sec>
      <sec id="article-30655.s7" sec-type="Complications">
        <title>Complications</title>
        <p>Pain at the injection site and itching can rarely occur with the TST.<xref ref-type="bibr" rid="article-30655.r37">[37]</xref> In healthcare workers, this was noted in 1.3% of tests.<xref ref-type="bibr" rid="article-30655.r37">[37]</xref> As the TST requires that the patient return to have the test read by experienced medical personnel, loss to follow-up is a concern, as patients will not receive any benefits from the testing in this circumstance.<xref ref-type="bibr" rid="article-30655.r38">[38]</xref> A study with a patient population consisting of those coping with housing instability and refugees noted that 79% of patients with an attempted TST returned to the clinic have it interpreted.<xref ref-type="bibr" rid="article-30655.r38">[38]</xref></p>
      </sec>
      <sec id="article-30655.s8" sec-type="Patient Safety and Education">
        <title>Patient Safety and Education</title>
        <p>Patients often have the misconception that a positive TST or IGRA indicates that they have active tuberculosis if thorough education is not provided. Patients should be educated regarding the rationale behind the testing ordered and counseled about what a positive result would mean in their specific context before the test is ordered. Patients should be thoroughly educated on the difference between LTBI and active tuberculosis, which can relieve significant emotional stress. If results are positive, patients should be educated about the importance of tuberculosis-preventative therapy in their specific context.</p>
      </sec>
      <sec id="article-30655.s9" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>LTBI is prevalent, and screening and treating patients at high risk of infection or progression to active disease reduces tuberculosis's global burden. The TST and IGRAs are available to evaluate for LTBI, although some populations have minor differences in their performance. A decision to test should presuppose the intention to treat LTBI if detected.</p>
      </sec>
      <sec id="article-30655.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30655&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30655">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30655/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30655">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30655.s11">
        <title>References</title>
        <ref id="article-30655.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drain</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Bajema</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dheda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meermeier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lewinsohn</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sherman</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30021818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dheda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Divangahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boehme</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Swaminathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spigelman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Getahun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Raviglione</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2016</year>
            <month>Oct</month>
            <day>27</day>
            <volume>2</volume>
            <fpage>16076</fpage>
            <pub-id pub-id-type="pmid">27784885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Priorities for the treatment of latent tuberculosis infection in the United States.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>May</month>
            <day>13</day>
            <volume>350</volume>
            <issue>20</issue>
            <fpage>2060</fpage>
            <page-range>2060-7</page-range>
            <pub-id pub-id-type="pmid">15141044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Basteiro</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Brew</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Borgdorff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cobelens</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>What is the true tuberculosis mortality burden? Differences in estimates by the World Health Organization and the Global Burden of Disease study.</article-title>
            <source>Int J Epidemiol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>1549</fpage>
            <page-range>1549-1560</page-range>
            <pub-id pub-id-type="pmid">30010785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Houben</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.</article-title>
            <source>PLoS Med</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e1002152</fpage>
            <pub-id pub-id-type="pmid">27780211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Churchyard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Rustomjee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mathema</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kasmar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cardenas</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>What We Know About Tuberculosis Transmission: An Overview.</article-title>
            <source>J Infect Dis</source>
            <year>2017</year>
            <month>Nov</month>
            <day>03</day>
            <volume>216</volume>
            <issue>suppl_6</issue>
            <fpage>S629</fpage>
            <page-range>S629-S635</page-range>
            <pub-id pub-id-type="pmid">29112747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Screening for Latent Tuberculosis Infection.</article-title>
            <source>JAMA Netw Open</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>e2312114</fpage>
            <pub-id pub-id-type="pmid">37129898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Tuberculin Skin Test Versus the Interferon-&#x003b3; Release Assays: Out With the Old, In With the New.</article-title>
            <source>Pediatrics</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>145</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31892521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kestler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tyler</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Latent tuberculosis testing through the ages: the search for a sleeping killer.</article-title>
            <source>Am J Physiol Lung Cell Mol Physiol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>322</volume>
            <issue>3</issue>
            <fpage>L412</fpage>
            <page-range>L412-L419</page-range>
            <pub-id pub-id-type="pmid">35170334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouwman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Thijsen</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Bossink</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Improving the timeframe between blood collection and interferon gamma release assay using T-Cell Xtend&#x000ae;.</article-title>
            <source>J Infect</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-203</page-range>
            <pub-id pub-id-type="pmid">22120115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nagaraja</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Schlesinger</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a modified interferon-gamma release assay for the diagnosis of latent tuberculosis infection in adult and paediatric populations that enables delayed processing.</article-title>
            <source>Scand J Infect Dis</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>11-12</issue>
            <fpage>845</fpage>
            <page-range>845-50</page-range>
            <pub-id pub-id-type="pmid">20608764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Advances in the diagnosis, treatment, and prevention of tuberculosis in children.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>301</fpage>
            <page-range>301-311</page-range>
            <pub-id pub-id-type="pmid">30648437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewinsohn</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>LoBue</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewinsohn</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Loeffler</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mazurek</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salfinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shinnick</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Warshauer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Jan</month>
            <day>15</day>
            <volume>64</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-115</page-range>
            <pub-id pub-id-type="pmid">28052967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pennie</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Mantoux tests. Performing, interpreting, and acting upon them.</article-title>
            <source>Can Fam Physician</source>
            <year>1995</year>
            <month>Jun</month>
            <volume>41</volume>
            <fpage>1025</fpage>
            <page-range>1025-9</page-range>
            <pub-id pub-id-type="pmid">7780314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shafeque</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bigio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banaei</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?</article-title>
            <source>J Clin Microbiol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>24</day>
            <volume>58</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">32493779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goletti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Delogu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matteelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection.</article-title>
            <source>Int J Infect Dis</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>124 Suppl 1</volume>
            <fpage>S12</fpage>
            <page-range>S12-S19</page-range>
            <pub-id pub-id-type="pmid">35257904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Indeterminate results of interferon gamma release assays in the screening of latent tuberculosis infection: a systematic review and meta-analysis.</article-title>
            <source>Front Immunol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1170579</fpage>
            <pub-id pub-id-type="pmid">37256138</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Clinical effect of T-SPOT.TB test for the diagnosis of tuberculosis.</article-title>
            <source>BMC Infect Dis</source>
            <year>2019</year>
            <month>Nov</month>
            <day>21</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>993</fpage>
            <pub-id pub-id-type="pmid">31752713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Upfal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adamo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernacki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kadlecek</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Humphrey-Carothers</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rielly</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Drewry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>DeWitt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Dea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Balser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wrighton-Smith</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>T-SPOT.TB Interferon-&#x003b3; Release Assay Performance in Healthcare Worker Screening at Nineteen U.S. Hospitals.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2015</year>
            <month>Aug</month>
            <day>01</day>
            <volume>192</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-73</page-range>
            <pub-id pub-id-type="pmid">26017193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wattal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raveendran</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Newer Diagnostic Tests and their Application in Pediatric TB.</article-title>
            <source>Indian J Pediatr</source>
            <year>2019</year>
            <month>May</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>441</fpage>
            <page-range>441-447</page-range>
            <pub-id pub-id-type="pmid">30628039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortiz-Brizuela</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Apriani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lachapelle-Chisholm</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miedy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Korobitsyn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Assessing the Diagnostic Performance of New Commercial Interferon-&#x003b3; Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review and Meta-Analysis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2023</year>
            <month>Jun</month>
            <day>08</day>
            <volume>76</volume>
            <issue>11</issue>
            <fpage>1989</fpage>
            <page-range>1989-1999</page-range>
            <pub-id pub-id-type="pmid">36688489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <article-title>Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>1995</year>
            <month>Sep</month>
            <day>08</day>
            <volume>44</volume>
            <issue>RR-11</issue>
            <fpage>19</fpage>
            <page-range>19-34</page-range>
            <pub-id pub-id-type="pmid">7565540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <source>WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1: prevention [Internet]</source>
            <publisher-name>World Health Organization</publisher-name>
            <publisher-loc>Geneva</publisher-loc>
            <year>2020</year>
            <pub-id pub-id-type="pmid">32186832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Rout</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ziehl-Neelsen sputum smear microscopy image database: a resource to facilitate automated bacilli detection for tuberculosis diagnosis.</article-title>
            <source>J Med Imaging (Bellingham)</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>027503</fpage>
            <pub-id pub-id-type="pmid">28680911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denkinger</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kik</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Rangaka</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Zwerling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oxlade</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dowdy</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dheda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Banaei</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gamma interferon release assays for detection of Mycobacterium tuberculosis infection.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-20</page-range>
            <pub-id pub-id-type="pmid">24396134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gundogdu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Aydogan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arisoy</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Gokalp</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Effect of number of BCG vaccination on tuberculin induration size.</article-title>
            <source>J Paediatr Child Health</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>6</issue>
            <fpage>476</fpage>
            <page-range>476-9</page-range>
            <pub-id pub-id-type="pmid">17535179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bugiani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borraccino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Migliore</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carosso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piccioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cavallero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caria</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Salamina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Arossa</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Tuberculin reactivity in adult BCG-vaccinated subjects: a cross-sectional study.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>320</fpage>
            <page-range>320-6</page-range>
            <pub-id pub-id-type="pmid">12729336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Host factors associated to false negative and indeterminate results in an interferon-&#x003b3; release assay in patients with active tuberculosis.</article-title>
            <source>Pulmonology</source>
            <year>2020</year>
            <season>Nov-Dec</season>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>353</fpage>
            <page-range>353-362</page-range>
            <pub-id pub-id-type="pmid">31843341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <article-title>Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2000</year>
            <month>Jun</month>
            <day>09</day>
            <volume>49</volume>
            <issue>RR-6</issue>
            <fpage>1</fpage>
            <page-range>1-51</page-range>
            <pub-id pub-id-type="pmid">10881762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Mazrou</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Booster effect of two-step tuberculin skin testing among hospital employees from areas with a high prevalence of tuberculosis.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>12</issue>
            <fpage>1117</fpage>
            <page-range>1117-20</page-range>
            <pub-id pub-id-type="pmid">15636304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>159</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">9872812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahwati</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Feltner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woodell</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amick</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Sep</month>
            <day>06</day>
            <volume>316</volume>
            <issue>9</issue>
            <fpage>970</fpage>
            <page-range>970-83</page-range>
            <pub-id pub-id-type="pmid">27599332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Winkler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frantal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Primas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miehsler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Angelberger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Novacek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mikulits</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vogelsang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reinisch</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Predictors of indeterminate IFN-&#x003b3; release assay in screening for latent TB in inflammatory bowel diseases.</article-title>
            <source>Eur J Clin Invest</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>1071</fpage>
            <page-range>1071-6</page-range>
            <pub-id pub-id-type="pmid">21413978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reading</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Capocci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seneviratne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cropley</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results.</article-title>
            <source>Eur Respir J</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>50</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29074546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharninghausen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Koelle</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>ofy184</fpage>
            <pub-id pub-id-type="pmid">30151410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Ortiz-Brizuela</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bastos</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Sep</month>
            <day>07</day>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>e1116</fpage>
            <page-range>e1116-e1125</page-range>
            <pub-id pub-id-type="pmid">33289038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christopher</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Datey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zwerling</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Safety of the two-step tuberculin skin test in Indian health care workers.</article-title>
            <source>Int J Mycobacteriol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>247</fpage>
            <page-range>247-51</page-range>
            <pub-id pub-id-type="pmid">26786623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30655.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewan</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Grinsdale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fallstad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kawamura</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay.</article-title>
            <source>BMC Infect Dis</source>
            <year>2006</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <fpage>47</fpage>
            <pub-id pub-id-type="pmid">16539718</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
